missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human LGI4 Synthetic Peptide
Description
This peptide corresponds to 14 amino acids near the center of human LGI4. PEP-0635 can be used as a blocking peptide with polyclonal antibody PA5-20515.
The leucine-rich, glioma inactivated gene 4 (LGI4) is a member of the LGI family in which LGI1 is the exemplar. The LGI family consists of four of highly related proteins containing leucine-rich repeats (LRRs) which are highly similar to other transmembrane signaling molecules and receptors. LGI1 has been identified as a candidate tumor suppressor gene for glioma and plays a role in autodominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms. Despite its high homology with LGI1 and similar pattern of expression, mutations in LGI4 have not been found to be associated with ADTLE. However, the LGI4 gene is located in a region linked to benign familial infantile convulsions. Further study revealed that a GC-to-AT polymorphism was correlated with childhood absence epilepsy. Other studies showed that decreasing LGI4 expression in cultured cells inhibits myelination, indicating that LGI4 may play a role in neural development.
Specifications
Specifications
| Gene ID (Entrez) | 163175 |
| Species | Human |
| Purification Method | purified |
| Accession Number | Q8N135 |
| Common Name | LGI4 |
| Concentration | 200 μg/mL |
| Content And Storage | -20°C |
| Description | Synthetic Peptide |
| Format | Liquid |
| Formulation | PBS with 0.1% BSA and 0.02% sodium azide; pH 7.2 |
| Show More |
Nom du produit
En cliquant sur Soumettre, vous reconnaissez que vous pouvez être contacté par Fisher Scientific au sujet des informations que vous avez fournies dans ce formulaire. Nous ne partagerons pas vos informations à d'autres fins. Toutes les informations de contact fournies seront également conservées conformément à notre politique de confidentialité. Politique de confidentialité.
Vous avez repéré une opportunité d'amélioration ?